MedTrace Logo

A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

NCT04464759 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2026-05-11

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.

Conditions

Interventions

DRUG

Nivolumab

Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

DRUG

Hydroxychloroquine

Combination of nivolumab and hydroxychloroquine OR nivolumab, hydroxychloroquine and ipilimumab

DRUG

Ipilimumab

Combination of nivolumab, hydroxychloroquine and ipilimumab

Sponsors & Collaborators

Principal Investigators

  • Ravi Amaravadi, MD · Abramson Cancer Center at Penn Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2027-01-06
Completion
2027-01-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04464759 on ClinicalTrials.gov